{"ticker": {"uuid": "c07c5d84-1780-4024-910b-5f641d188c82", "symbol": "ZURA", "name": "Zura Bio Limited Class A Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNMjNYbmJuX0ktWFhDSkdrS25udDU0VXY2ckZ3dXFCdFZuNS14WWdKNEVXMWNVV0l5SElOTEVLelBXY3BBRUptS2NLQnZQZ1VjdFhHcVZPRUwzcEFQcmNxb1BhTkh0TVlWR29taTlPU0ZpblVDVEtNMmNCS3NaMXoxaVBiU3I0OE4zdGhVX0ktMWVtdDdhZWR1VHlUY00xRXE0ajFTekM4aEZieXF6VVVhWk00Qy1KU1c5U1FHb3RlX2xsUGh0QU9jcW9aQjZhbkxqSGpHWDFnTDgyeDlnblFlOVN6VQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-08T17:24:08+00:00", "published_display": "08 Jul 2026 17:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zura Bio Limited \u2013 NASDAQ:ZURA", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVGJiR256SHV3ZEZMT2NaODVlU2drcVlMWi1CYXFVcEJxNFdaa2llbjBhRFBfSHgzNlkwMHRUdUVVUGJpMEc1NlZETWRKQlY2cHN5VFEwNGo0ajZEYmhsY3p5ekIwQmlrTjRRUEotSmJxRmtqMTFubnJtaXc0UjJwSnd3Qld3b0c5cW9HaUZHWEJSWFp4TEZPTHB4T3NEZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T15:46:02+00:00", "published_display": "06 Jul 2026 15:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors", "summary": "Zura Bio Limited has released an updated corporate presentation dated July 1, 2026, for upcoming investor meetings and conferences. This presentation, furnished as Exhibit 99.1 to a Form 8-K filing, details the company's lead program, tibulizumab, a bispecific antibody targeting ", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-024fb762c315.html", "source_name": "Stock Titan", "published_at": "2026-07-01T10:39:30", "published_display": "01 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQdW16N0h1bkg0UUJweXFpbEJHZGI2Nlp2ZUlwekhncU53QXZvY1VGUWZqRkw2eWdGR1I2Tkx5dXYzdnpYeVVnc1UweWVYOTdHVzdHZVBPREttdlRIWlJkSGFCMFVZZjZyQmJhdkVCSUE2cHVDQVFWZzIyUlEyS3ladGpfdHpKSVQxaHVCVW5pMVpnVFc4Y24wamJfbUdHM3M5NWZDLTVIaldQRDdDWjJsWjh4anM?oc=5", "source_name": "Sahm", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) VP details share, RSU and option holdings", "summary": "Zura Bio's VP and Principal Accounting Officer, Mathew Marlyn Teresa, reported his holdings as per a Form 3 filing. He holds 129,182 Class A ordinary shares, including 32,296 shares underlying restricted stock units that will vest in May 2027. Additionally, he possesses several e", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-3-zura-bio-ltd-initial-statement-of-beneficial-ownership-0be960c3cdce.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:11:42", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options", "summary": "Zura Bio Ltd. director Jennifer Jarrett received a grant of 51,000 Class A Ordinary Share options with an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over one year, starting June 17, 2026, contingent on ", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-7892e1a4b02a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:11:42", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director awarded 51,000 share options at $3.62", "summary": "Zura Bio Ltd. director Parvinder Thiara was granted 51,000 share options for Class A Ordinary Shares at an exercise price of $3.62, expiring on June 17, 2036. The options will vest in twelve equal monthly installments starting June 17, 2026, contingent on Thiara's continued servi", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-c2cd197ee1bc.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:43", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director receives grant of 51,000 stock options", "summary": "Zura Bio Ltd. director Steven J. Schoch was granted 51,000 stock options as compensation. These options allow him to buy Class A Ordinary Shares at an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over a o", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-1746546729fb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options", "summary": "Zura Bio Ltd director Ajay Nirula was granted 51,000 share options at an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over one year starting June 17, 2026, contingent on his continued service. This transa", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-0fd084dbe4f2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price", "summary": "Zura Bio Ltd. director Mark Eisner was granted 51,000 share options for Class A Ordinary Shares with an exercise price of $3.62 per share, expiring on June 17, 2036. This compensation-related award vests in monthly installments over one year, subject to his continued service. Fol", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-1acb3ffcf7a2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes", "summary": "Zura Bio Limited shareholders approved the re-election of all eight director nominees, ratified the appointment of WithumSmith+Brown, PC as their independent registered public accounting firm for the fiscal year ending December 31, 2026, and adopted changes to their 2023 Equity I", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-4887e29057d7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:58", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQWndzOFBuNzg5NVU4MlhTS3Bnd1pvZ1pWTzh4WU9jTDA1bXhIc3hRZW9kQ2tyNFgyNkp0UHE2czRMRFl0aFVNRUVhbU8xS2J5b2pGYUNIUnNGRGpUTXNPQXVVWHZCeVV1YXN6cWVsVXZJcWpoRno1X0p2TWgxUHAzM25OUF9pNUYtTTVINEZIckk?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "65,018,058 Class A Ordinary Shares of Zura Bio Limited are subject to a Lock-Up Agreement Ending on 26-MAY-2026.", "summary": "65,018,058 Class A Ordinary Shares of Zura Bio Limited are under a 91-day lock-up agreement, preventing executive officers and directors from selling or transferring them. This lock-up period began on February 24, 2026, and will end on May 26, 2026. The agreement is designed to m", "url": "https://www.marketscreener.com/news/65-018-058-class-a-ordinary-shares-of-zura-bio-limited-are-subject-to-a-lock-up-agreement-ending-on-ce7f5addda8df025", "source_name": "www.marketscreener.com", "published_at": "2026-05-26T08:37:00", "published_display": "26 May 2026 08:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu", "summary": "Zura Bio Limited (NASDAQ: ZURA) has announced the resignation of director Someit Sidhu from its board of directors, effective May 21, 2026. The company stated that Sidhu's resignation was not due to any disagreements regarding its operations, policies, or practices. This informat", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-d3354b513da4.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:09:05", "published_display": "22 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Venrock entities report 9.99% ownership in ZURA (ZURA)", "summary": "Venrock-affiliated entities have filed an amended Schedule 13G reporting a beneficial ownership of 9.99% in Zura Bio Ltd (ZURA) as of March 31, 2026. This ownership is capped at 9,816,384 Class A Ordinary Shares due to a \"Beneficial Ownership Blocker\" provision within Pre-Funded ", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-6c0f4a1dd7fd.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:29", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA)", "summary": "Great Point Partners, Dr. Jeffrey R. Jay, and Ms. Lillian Nordahl have jointly reported a beneficial ownership of 4,215,930 Class A Ordinary Shares in Zura Bio Limited (ZURA), representing 4.44% of the class. This disclosure was made via a Schedule 13G/A filing, indicating a pass", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-1dcb6e14f650.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:09:29", "published_display": "15 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "Zura Bio Limited announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted an option to purchase up to 600,000 Class A Ordinary Shares to its new Chief Business Officer, Muzammil Mustufa, with an exercise price of $4.80 per share. This award was approv", "url": "https://www.businesswire.com/news/home/20260514672655/en/Zura-Bio-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-05-15T01:08:53", "published_display": "15 May 2026 01:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zura Bio's new CBO gets options on 600,000 shares at $4.80", "summary": "Zura Bio Limited granted its new Chief Business Officer, Muzammil Mustufa, an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares. The option has an exercise price of $4.80 per share, equal to the closing price on May 13, 2026, and will vest", "url": "https://www.stocktitan.net/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-cmbgn66qar3h.html", "source_name": "Stock Titan", "published_at": "2026-05-13T04:39:28", "published_display": "13 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Zura Bio Ltd Amended Passive Investment Disclosure", "summary": "This SEC filing (SCHEDULE 13G/A) details an amended passive investment disclosure for Zura Bio Limited (ZURA) as of March 31, 2026. Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen are identified as reporting persons, collectively holding 9.9% of Class", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-be6b71154b6e.html", "source_name": "Stock Titan", "published_at": "2026-05-12T22:15:35", "published_display": "12 May 2026 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens", "summary": "Zura Bio reported a wider net loss of $24.2 million for Q1 2026, compared to $17.4 million a year prior, as the company significantly increased its research and development spending. This expanded R&D is primarily focused on advancing Phase 2 trials for its lead antibody, tibuliz", "url": "https://www.stocktitan.net/sec-filings/ZURA/10-q-zura-bio-ltd-quarterly-earnings-report-1b3cbc16d3a9.html", "source_name": "Stock Titan", "published_at": "2026-05-08T09:40:42", "published_display": "08 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M", "summary": "Zura Bio (Nasdaq: ZURA) reported a widened net loss of $24.2 million, or $0.22 per share, in Q1 2026, up from $17.4 million in Q1 2025, due to increased R&D and G&A expenses as it advances its immunology pipeline. The company significantly boosted its cash and cash equivalents to", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-c14f7f96fae2.html", "source_name": "Stock Titan", "published_at": "2026-05-07T11:40:04", "published_display": "07 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) \u2014 4.7% stake", "summary": "JPMorgan Chase has filed an amended Schedule 13G/A, reporting a beneficial ownership of 4,471,316 Class A Ordinary Shares in Zura Bio Ltd (NASDAQ: ZURA), which represents a 4.7% stake. The filing indicates a passive investment with JPMorgan having sole voting and dispositive powe", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-742d64ccdfdd.html", "source_name": "Stock Titan", "published_at": "2026-05-06T18:10:19", "published_display": "06 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eight new Zura Bio hires get options tied to 615,160 shares", "summary": "Zura Bio Limited announced that it granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares to eight newly hired employees on April 30, 2026. These awards, approved by the Compensation Committee, are outside the Company's 2023 Equity Incen", "url": "https://www.stocktitan.net/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-okaer7lj3q36.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:10:19", "published_display": "04 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares", "summary": "Zura Bio Ltd. (ZURA) CEO Sandeep Chidambar Kulkarni was granted options on 894,000 Class A Ordinary Shares. These options have an exercise price of $6.03 per share and expire on April 1, 2036. The options will vest one-fourth on April 1, 2027, with the remainder vesting quarterly", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-06bdc87dce86.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:02", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver (NASDAQ:ZURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPYzdlRTMzcThLWEFMdlEtQXl0SmdOblM1LTlCUTRfUl8zaWI5SXItbER3TGZrY2lhaWRwaklRZHEyTDljdlZ0MV9hd2w3TjNqM3Rrd3J6ZndGQnk0ZHhBUXVaeWlyd0g2WmROLXR6Z2xMRVBtRGJMS2dMdTI0dWVJLV9iWEl2VUpCSk1Mc1Y4NDlPdkhqemlxYW9EWW5Gak0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxNWnRSY0pQcHlsdTdseTZMbS1IcS1LUjdaQ3hBdHNOVDh6Q2E1OUZjMkhZX1Y5N3BfX2VYejRiRklLQmxpMm9pVF9ZakMtMkw4LUpoaEJqOWpEZkI0MG1pQ0dzX2NTV1Z4QkhibkNLTUJQVkx0dU1BX3IxbDdaOVNkZ0g2UGg0UXlxNktseGQybkRjLXViTXJ3bHJPTHBvS0VTUEpseElsME4xdDI3Y1phT0pzY2RObGFRZTJNSzZTb3c1bmlPQjgxcWdGTFBFdHgtUWswSmY4anNYLVNKODlqR0w2emJKLTRSUXByRUZGYVFJdnRtb3BBdWI1MXFKYjRuMWpDdTM3QzB0MTltYXNPcWpEcGstbFZzUTE4TmxFa1ZNQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNNmFHYlVFSm5TcDNlWWRad1RVX202QVExRm0yb2stQlA3LW1HV1I5R1ROVHNaU3JPWV8wVFFzd256VWVhOUlNNVdKZUFkZFo4VEROZTZhZTNfR21vaGNTeVlQOG1VUHV5MGRNVWpVU3BrOFJpODFGc3NYb2NXdGJiMWk5TmVLTXI5UExJOEhBLTBqQndaWTBaZ1pWVndpYUdOc09R?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxNMjNYbmJuX0ktWFhDSkdrS25udDU0VXY2ckZ3dXFCdFZuNS14WWdKNEVXMWNVV0l5SElOTEVLelBXY3BBRUptS2NLQnZQZ1VjdFhHcVZPRUwzcEFQcmNxb1BhTkh0TVlWR29taTlPU0ZpblVDVEtNMmNCS3NaMXoxaVBiU3I0OE4zdGhVX0ktMWVtdDdhZWR1VHlUY00xRXE0ajFTekM4aEZieXF6VVVhWk00Qy1KU1c5U1FHb3RlX2xsUGh0QU9jcW9aQjZhbkxqSGpHWDFnTDgyeDlnblFlOVN6VQ?oc=5", "source_name": "Benzinga", "published_at": "2026-07-08T17:24:08+00:00", "published_display": "08 Jul 2026 17:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zura Bio Limited \u2013 NASDAQ:ZURA", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVGJiR256SHV3ZEZMT2NaODVlU2drcVlMWi1CYXFVcEJxNFdaa2llbjBhRFBfSHgzNlkwMHRUdUVVUGJpMEc1NlZETWRKQlY2cHN5VFEwNGo0ajZEYmhsY3p5ekIwQmlrTjRRUEotSmJxRmtqMTFubnJtaXc0UjJwSnd3Qld3b0c5cW9HaUZHWEJSWFp4TEZPTHB4T3NEZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T15:46:02+00:00", "published_display": "06 Jul 2026 15:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors", "summary": "Zura Bio Limited has released an updated corporate presentation dated July 1, 2026, for upcoming investor meetings and conferences. This presentation, furnished as Exhibit 99.1 to a Form 8-K filing, details the company's lead program, tibulizumab, a bispecific antibody targeting ", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-024fb762c315.html", "source_name": "Stock Titan", "published_at": "2026-07-01T10:39:30", "published_display": "01 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQdW16N0h1bkg0UUJweXFpbEJHZGI2Nlp2ZUlwekhncU53QXZvY1VGUWZqRkw2eWdGR1I2Tkx5dXYzdnpYeVVnc1UweWVYOTdHVzdHZVBPREttdlRIWlJkSGFCMFVZZjZyQmJhdkVCSUE2cHVDQVFWZzIyUlEyS3ladGpfdHpKSVQxaHVCVW5pMVpnVFc4Y24wamJfbUdHM3M5NWZDLTVIaldQRDdDWjJsWjh4anM?oc=5", "source_name": "Sahm", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) VP details share, RSU and option holdings", "summary": "Zura Bio's VP and Principal Accounting Officer, Mathew Marlyn Teresa, reported his holdings as per a Form 3 filing. He holds 129,182 Class A ordinary shares, including 32,296 shares underlying restricted stock units that will vest in May 2027. Additionally, he possesses several e", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-3-zura-bio-ltd-initial-statement-of-beneficial-ownership-0be960c3cdce.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:11:42", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options", "summary": "Zura Bio Ltd. director Jennifer Jarrett received a grant of 51,000 Class A Ordinary Share options with an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over one year, starting June 17, 2026, contingent on ", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-7892e1a4b02a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T04:11:42", "published_display": "23 Jun 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director awarded 51,000 share options at $3.62", "summary": "Zura Bio Ltd. director Parvinder Thiara was granted 51,000 share options for Class A Ordinary Shares at an exercise price of $3.62, expiring on June 17, 2036. The options will vest in twelve equal monthly installments starting June 17, 2026, contingent on Thiara's continued servi", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-c2cd197ee1bc.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:43", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director receives grant of 51,000 stock options", "summary": "Zura Bio Ltd. director Steven J. Schoch was granted 51,000 stock options as compensation. These options allow him to buy Class A Ordinary Shares at an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over a o", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-1746546729fb.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Zura Bio (NASDAQ: ZURA) granted 51,000 stock options", "summary": "Zura Bio Ltd director Ajay Nirula was granted 51,000 share options at an exercise price of $3.62 per share, expiring on June 17, 2036. The options will vest in twelve equal monthly installments over one year starting June 17, 2026, contingent on his continued service. This transa", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-0fd084dbe4f2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) director receives 51,000 share options at $3.62 strike price", "summary": "Zura Bio Ltd. director Mark Eisner was granted 51,000 share options for Class A Ordinary Shares with an exercise price of $3.62 per share, expiring on June 17, 2036. This compensation-related award vests in monthly installments over one year, subject to his continued service. Fol", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-1acb3ffcf7a2.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:11:42", "published_display": "22 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) investors approve board slate, auditor and 2023 equity plan changes", "summary": "Zura Bio Limited shareholders approved the re-election of all eight director nominees, ratified the appointment of WithumSmith+Brown, PC as their independent registered public accounting firm for the fiscal year ending December 31, 2026, and adopted changes to their 2023 Equity I", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-4887e29057d7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:39:58", "published_display": "18 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQWndzOFBuNzg5NVU4MlhTS3Bnd1pvZ1pWTzh4WU9jTDA1bXhIc3hRZW9kQ2tyNFgyNkp0UHE2czRMRFl0aFVNRUVhbU8xS2J5b2pGYUNIUnNGRGpUTXNPQXVVWHZCeVV1YXN6cWVsVXZJcWpoRno1X0p2TWgxUHAzM25OUF9pNUYtTTVINEZIckk?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "65,018,058 Class A Ordinary Shares of Zura Bio Limited are subject to a Lock-Up Agreement Ending on 26-MAY-2026.", "summary": "65,018,058 Class A Ordinary Shares of Zura Bio Limited are under a 91-day lock-up agreement, preventing executive officers and directors from selling or transferring them. This lock-up period began on February 24, 2026, and will end on May 26, 2026. The agreement is designed to m", "url": "https://www.marketscreener.com/news/65-018-058-class-a-ordinary-shares-of-zura-bio-limited-are-subject-to-a-lock-up-agreement-ending-on-ce7f5addda8df025", "source_name": "www.marketscreener.com", "published_at": "2026-05-26T08:37:00", "published_display": "26 May 2026 08:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) discloses resignation of director Someit Sidhu", "summary": "Zura Bio Limited (NASDAQ: ZURA) has announced the resignation of director Someit Sidhu from its board of directors, effective May 21, 2026. The company stated that Sidhu's resignation was not due to any disagreements regarding its operations, policies, or practices. This informat", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-d3354b513da4.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:09:05", "published_display": "22 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Venrock entities report 9.99% ownership in ZURA (ZURA)", "summary": "Venrock-affiliated entities have filed an amended Schedule 13G reporting a beneficial ownership of 9.99% in Zura Bio Ltd (ZURA) as of March 31, 2026. This ownership is capped at 9,816,384 Class A Ordinary Shares due to a \"Beneficial Ownership Blocker\" provision within Pre-Funded ", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-6c0f4a1dd7fd.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:29", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Great Point Partners, Dr. Jay & Nordahl report 4.44% in ZURA (ZURA)", "summary": "Great Point Partners, Dr. Jeffrey R. Jay, and Ms. Lillian Nordahl have jointly reported a beneficial ownership of 4,215,930 Class A Ordinary Shares in Zura Bio Limited (ZURA), representing 4.44% of the class. This disclosure was made via a Schedule 13G/A filing, indicating a pass", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-1dcb6e14f650.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:09:29", "published_display": "15 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "Zura Bio Limited announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted an option to purchase up to 600,000 Class A Ordinary Shares to its new Chief Business Officer, Muzammil Mustufa, with an exercise price of $4.80 per share. This award was approv", "url": "https://www.businesswire.com/news/home/20260514672655/en/Zura-Bio-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-05-15T01:08:53", "published_display": "15 May 2026 01:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio's new CBO gets options on 600,000 shares at $4.80", "summary": "Zura Bio Limited granted its new Chief Business Officer, Muzammil Mustufa, an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares. The option has an exercise price of $4.80 per share, equal to the closing price on May 13, 2026, and will vest", "url": "https://www.stocktitan.net/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-cmbgn66qar3h.html", "source_name": "Stock Titan", "published_at": "2026-05-13T04:39:28", "published_display": "13 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Zura Bio Ltd Amended Passive Investment Disclosure", "summary": "This SEC filing (SCHEDULE 13G/A) details an amended passive investment disclosure for Zura Bio Limited (ZURA) as of March 31, 2026. Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen are identified as reporting persons, collectively holding 9.9% of Class", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-be6b71154b6e.html", "source_name": "Stock Titan", "published_at": "2026-05-12T22:15:35", "published_display": "12 May 2026 22:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (NASDAQ: ZURA) boosts cash with $134.6M raise as R&D loss deepens", "summary": "Zura Bio reported a wider net loss of $24.2 million for Q1 2026, compared to $17.4 million a year prior, as the company significantly increased its research and development spending. This expanded R&D is primarily focused on advancing Phase 2 trials for its lead antibody, tibuliz", "url": "https://www.stocktitan.net/sec-filings/ZURA/10-q-zura-bio-ltd-quarterly-earnings-report-1b3cbc16d3a9.html", "source_name": "Stock Titan", "published_at": "2026-05-08T09:40:42", "published_display": "08 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchases Worth US$12.5m See Losses As Zura Bio Market Value Drops To US$464m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (Nasdaq: ZURA) widens Q1 loss, boosts cash to $225.6M", "summary": "Zura Bio (Nasdaq: ZURA) reported a widened net loss of $24.2 million, or $0.22 per share, in Q1 2026, up from $17.4 million in Q1 2025, due to increased R&D and G&A expenses as it advances its immunology pipeline. The company significantly boosted its cash and cash equivalents to", "url": "https://www.stocktitan.net/sec-filings/ZURA/8-k-zura-bio-ltd-reports-material-event-c14f7f96fae2.html", "source_name": "Stock Titan", "published_at": "2026-05-07T11:40:04", "published_display": "07 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) \u2014 4.7% stake", "summary": "JPMorgan Chase has filed an amended Schedule 13G/A, reporting a beneficial ownership of 4,471,316 Class A Ordinary Shares in Zura Bio Ltd (NASDAQ: ZURA), which represents a 4.7% stake. The filing indicates a passive investment with JPMorgan having sole voting and dispositive powe", "url": "https://www.stocktitan.net/sec-filings/ZURA/schedule-13g-a-zura-bio-ltd-amended-passive-investment-disclosure-742d64ccdfdd.html", "source_name": "Stock Titan", "published_at": "2026-05-06T18:10:19", "published_display": "06 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eight new Zura Bio hires get options tied to 615,160 shares", "summary": "Zura Bio Limited announced that it granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares to eight newly hired employees on April 30, 2026. These awards, approved by the Compensation Committee, are outside the Company's 2023 Equity Incen", "url": "https://www.stocktitan.net/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-okaer7lj3q36.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:10:19", "published_display": "04 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares", "summary": "Zura Bio Ltd. (ZURA) CEO Sandeep Chidambar Kulkarni was granted options on 894,000 Class A Ordinary Shares. These options have an exercise price of $6.03 per share and expire on April 1, 2036. The options will vest one-fourth on April 1, 2027, with the remainder vesting quarterly", "url": "https://www.stocktitan.net/sec-filings/ZURA/form-4-zura-bio-ltd-insider-trading-activity-06bdc87dce86.html", "source_name": "Stock Titan", "published_at": "2026-04-02T22:10:02", "published_display": "02 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver (NASDAQ:ZURA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPYzdlRTMzcThLWEFMdlEtQXl0SmdOblM1LTlCUTRfUl8zaWI5SXItbER3TGZrY2lhaWRwaklRZHEyTDljdlZ0MV9hd2w3TjNqM3Rrd3J6ZndGQnk0ZHhBUXVaeWlyd0g2WmROLXR6Z2xMRVBtRGJMS2dMdTI0dWVJLV9iWEl2VUpCSk1Mc1Y4NDlPdkhqemlxYW9EWW5Gak0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxNWnRSY0pQcHlsdTdseTZMbS1IcS1LUjdaQ3hBdHNOVDh6Q2E1OUZjMkhZX1Y5N3BfX2VYejRiRklLQmxpMm9pVF9ZakMtMkw4LUpoaEJqOWpEZkI0MG1pQ0dzX2NTV1Z4QkhibkNLTUJQVkx0dU1BX3IxbDdaOVNkZ0g2UGg0UXlxNktseGQybkRjLXViTXJ3bHJPTHBvS0VTUEpseElsME4xdDI3Y1phT0pzY2RObGFRZTJNSzZTb3c1bmlPQjgxcWdGTFBFdHgtUWswSmY4anNYLVNKODlqR0w2emJKLTRSUXByRUZGYVFJdnRtb3BBdWI1MXFKYjRuMWpDdTM3QzB0MTltYXNPcWpEcGstbFZzUTE4TmxFa1ZNQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNNmFHYlVFSm5TcDNlWWRad1RVX202QVExRm0yb2stQlA3LW1HV1I5R1ROVHNaU3JPWV8wVFFzd256VWVhOUlNNVdKZUFkZFo4VEROZTZhZTNfR21vaGNTeVlQOG1VUHV5MGRNVWpVU3BrOFJpODFGc3NYb2NXdGJiMWk5TmVLTXI5UExJOEhBLTBqQndaWTBaZ1pWVndpYUdOc09R?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 36, "sentiment_summary": {"positive": 5, "negative": 2, "neutral": 29, "score": 52, "total": 36, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.11, "latest_week": "2026-07-10", "one_week_move": -1.2, "four_week_move": 38.1, "twelve_week_move": -12.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.186611, "market_dynamics_buy_signal": false, "relative_strength": 3.642106, "fair_value_gap": 35.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.3845, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, +38.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "Benzinga", "count": 1}, {"label": "Sahm", "count": 1}, {"label": "www.marketscreener.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 28}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 8}, {"label": "Balance sheet", "count": 4}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "28", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.2% over one week, +38.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "What's Going on With Zura Bio Stock Wednesday? - Zura Bio (NASDAQ:ZURA)"}], "updated_at": "2026-07-16T13:32:12.825822+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}